Patents Issued in October 18, 2016
  • Patent number: 9468648
    Abstract: Naturally occurring lecithins and/or oleic acid stimulate the growth and lactic acid producing activity of Lactobacillus and Bifidobacterium species of probiotic bacteria, and replace polysorbate 80 for those products. They can be used in naturally occurring form, or where they are to be combined with probiotics in a carrier, or they can be treated to yield a stable powdered form of these naturally oily compounds. They can be sold as combined prebiotic/probiotic formulations in the same carrier, or sold as separate dietary supplements, e.g., in capsule or tablet form, to be used with the probiotic formulation as desired.
    Type: Grant
    Filed: May 30, 2013
    Date of Patent: October 18, 2016
    Assignee: MASTER SUPPLEMENTS, INC.
    Inventors: Sonja Lea Yonak, Randolph S. Porubcan
  • Patent number: 9468649
    Abstract: The present invention provides methods of treating epilepsy and other neurological disorders. The methods generally involve administering to an individual in need thereof an effective amount of an agent that blocks a transforming growth factor-beta pathway.
    Type: Grant
    Filed: December 4, 2009
    Date of Patent: October 18, 2016
    Assignee: The Regents of the University of California
    Inventors: Daniela Kaufer, Alon Friedman, Luisa Cacheaux
  • Patent number: 9468650
    Abstract: The present invention relates, in general, to pattern-recognition receptors (PRRs), including toll-like receptors (TLRs), and, in particular, to a method of inhibiting nucleic acid-induced activation of, for example, endosomal TLRs using an agent that binds to the nucleic acid (“nucleic acid binding agent”), preferably, in a manner that is independent of the nucleotide sequence, the chemistry (e.g., DNA or RNA, with or without base or sugar modifications) and/or the structure (e.g., double-stranded or single-stranded, complexed or uncomplexed with, for example protein) of the nucleic acid(s) responsible for inducing TLR activation. The invention also relates to methods of identifying nucleic acid binding agents suitable for use in such methods.
    Type: Grant
    Filed: September 16, 2010
    Date of Patent: October 18, 2016
    Assignee: DUKE UNIVERSITY
    Inventors: Bruce A. Sullenger, Jaewoo Lee
  • Patent number: 9468651
    Abstract: A method for removing moles includes applying a composition containing potassium hydroxide, Beijing Er Guo Tou and talcum powder on the surface of moles on human skin. The composition is applicable to benign moles and not to cancerous moles.
    Type: Grant
    Filed: December 30, 2009
    Date of Patent: October 18, 2016
    Inventor: Yuk Ming To
  • Patent number: 9468652
    Abstract: Some embodiments of the present disclosure include a dental gel formulation for protecting a user's teeth and gums from acid resulting from acid reflux disease or bacterial plaque. The dental gel may include a gel carrier and a treatment ingredient, the treatment ingredient being a member selected from the group consisting of an antibacterial ingredient, an acid neutralizing ingredient, a vitamin, a mineral ingredient, a probiotic, natural extracts and oils, and medication. In some embodiments, the gel carrier may be a poloxamer 407 gel, and the treatment ingredients may include sodium bicarbonate, calcium carbonate, xylitol, and optionally melatonin.
    Type: Grant
    Filed: July 15, 2014
    Date of Patent: October 18, 2016
    Inventor: Michael Yar Zuk
  • Patent number: 9468653
    Abstract: The present invention relates to the a bismuth-based composition, particularly involving the use of bismuth ions, particularly the Bi+3 ion, for prevention and/or treatment of the haemolytic uremic syndrome, with the invention also relating to the use of a bismuth ion in the manufacture of a medicament for the prevention and/or treatment of an infection caused by a Shiga-toxin producing Escherichia coli strain, as well as to a method for preventing and/or treating the haemolytic uremic syndrome comprising administering bismuth ions to a patient in need thereof, and a method for inhibiting dissemination of the gene encoding virulence factors of a Shiga-toxin producing Escherichia coli strain in animals and humans.
    Type: Grant
    Filed: October 10, 2011
    Date of Patent: October 18, 2016
    Assignee: Soubeiran Chobet
    Inventor: Hector Manuel Fernandez
  • Patent number: 9468654
    Abstract: A drug delivery composition is disclosed which includes a triple salt proxy functional group and at least one amino acid functional group. A method of forming the drug delivery composition includes reacting a triple salt with at least one amino acid in an aqueous environment. A biodegradable fabric is disclosed which includes a polymerized structure of a triple salt proxy functional group and at least one amino acid functional group.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: October 18, 2016
    Inventor: Ali Razavi
  • Patent number: 9468655
    Abstract: Compositions and methods are disclosed herein for producing one or more immunoglobulins in an isolated B lymphocyte cell line. An isolated recombinant cell line includes an isolated B lymphocyte cell line capable of expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and at least one exogenously incorporated nucleic acid encoding at least one secreted immunoglobulin reactive to a second antigen.
    Type: Grant
    Filed: February 17, 2015
    Date of Patent: October 18, 2016
    Assignee: Elwha LLC
    Inventors: Roderick A. Hyde, Wayne R. Kindsvogel
  • Patent number: 9468656
    Abstract: The present invention relates to a method of preparing cells and in particular to a method of preparing breastmilk stem cells (BSCs) by isolation from breastmilk and subsequent culture. The invention further relates to BSCs prepared by the methods of the invention and to methods and uses thereof. In one aspect, the invention has been developed as a method for preparing and culturing BSC.
    Type: Grant
    Filed: August 12, 2014
    Date of Patent: October 18, 2016
    Assignee: Medela Holding AG
    Inventor: Foteini Kakulas
  • Patent number: 9468657
    Abstract: This invention provides an effective means or method for improving lipid metabolism, and a means or method for treatment or prevention of diseases or disorders associated with the lipid metabolism disorder. Specifically, this invention relates to an agent for improving the lipid metabolism comprising, as active ingredients, broken cells of a lactic acid bacterium, and to a method for enhancing an effect of a lactic acid bacterium for improving the lipid metabolism comprising a step of breaking the lactic acid bacterium.
    Type: Grant
    Filed: June 8, 2011
    Date of Patent: October 18, 2016
    Assignee: Asahi Group Holdings, Ltd.
    Inventors: Futoshi Nakamura, Yu Ishida, Shigeru Fujiwara
  • Patent number: 9468658
    Abstract: The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: October 18, 2016
    Assignee: Crestovo LLC
    Inventor: Thomas Julius Borody
  • Patent number: 9468659
    Abstract: Compositions and uses thereof include an admixture of a probiotic and natural phytochemicals that can affect an individual's stem cells and the inflammatory process to reduce underlying symptoms of various health issues, including arthritis, aging, and physical or athletic injuries, thereby facilitating healing and repair of tissues.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: October 18, 2016
    Assignee: NWO STEM CURE, LLC
    Inventors: Bruce E. Heck, Dong Hyun Kim
  • Patent number: 9468660
    Abstract: There are provided methods and compositions useful in cell-cell fusion using Fusion Family (FF) proteins of nematode origin. There are further provided antinematodal methods and compositions, utilizing fusogenic proteins of the nematode Fusion Family.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: October 18, 2016
    Assignees: Technion Research and Development Foundation Ltd., University of Virginia Patent Foundation
    Inventors: Benjamin Podbilewicz, Ori Avinoam, Judith M. White
  • Patent number: 9468661
    Abstract: The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as complement pathway modulators for the treatment of ocular diseases. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: October 18, 2016
    Assignee: Novartis AG
    Inventors: Eva Altmann, Ulrich Hommel, Edwige Liliane Jeanne Lorthiois, Jeurgen Klaus Maibaum, Nils Ostermann, Jean Quancard, Stefan Andreas Randl, Olivier Rogel, Anna Vulpetti
  • Patent number: 9468662
    Abstract: A PAT nonapeptide of formula EAKSQGGSD (SEQ ID NO: 1) can be used to treat or prevent neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis. Pharmaceutical compositions containing the PAT nonapeptide can be formulated for administration by parenteral route, including the subcutaneous, intraperitoneal, intravenous or intranasal routes.
    Type: Grant
    Filed: November 2, 2015
    Date of Patent: October 18, 2016
    Assignee: ORPHIT
    Inventors: Claude Laruelle, Jamal Temsamani, Frederic Mourlane
  • Patent number: 9468663
    Abstract: There is disclosed herein a composition for treating gastrointestinal or neurological disorders, constipation, functional constipation, irritable bowel syndrome, diverticulitis, travelers diarrhoea, chronic idiopathic nausea, IBD-associated constipation and diarrhoea, pseudo-obstruction, diabetic gastroparesis, cyclic vomiting, reflux oesophagitis, autism enteropathy, flatulence, halitosis, chronic fatigue, bloating, proctalgia fugax, Parkinsons disease, MS, Alzheimers Disease, Motor Neurone Disease or autism, the composition comprising: (i) at least two anti-clostridial agents selected from the group consisting of: vancomycin, vancomycin derivatives, a multi-valent polymer of vancomycin, aminoglycosides, nitroimidazoles, ansamysins, nifuroxazide, colchicine, prucalopride, prokinetic agent and 5-aminosalicylic acid; or (ii) at least one anti-clostridial agent selected from the above combined with an opioid blocking agent.
    Type: Grant
    Filed: July 23, 2015
    Date of Patent: October 18, 2016
    Inventor: Thomas Julius Borody
  • Patent number: 9468664
    Abstract: Provided herein are liquid concentrate formulations of romidepsin. Also provided are methods for producing these formulations and uses thereof. In one embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and a citrate buffer. In another embodiment, the formulation comprises romidepsin, polyethylene glycol, etanol and an acetate buffer.
    Type: Grant
    Filed: November 17, 2015
    Date of Patent: October 18, 2016
    Assignee: Celgene Corporation
    Inventors: Lianfeng Huang, Ho-Wah Hui, Vijay Naringrekar, Gang Yang
  • Patent number: 9468665
    Abstract: Nerve Growth Factor (NGF), in the form of a preparation to be administered over ocular surface, is suggested as being suitable for therapy and/or prophylaxis of intraocular tissue pathologies, with particular reference to sclera, ciliary body, crystalline lens, retina, optic nerve, vitreous body and choroidea affections. When administered in the form of external ophthalmic preparation, for example as collyrium or ointment, NGF is capable to go through ocular tissues and it has been found out that it shows a therapeutic activity not only against retina and optic nerve pathologies but also against affections involving the above reported internal structures of the eye.
    Type: Grant
    Filed: January 21, 2000
    Date of Patent: October 18, 2016
    Assignee: Dompé Farmaceutici S.p.A.
    Inventor: Alessandro Lambiase
  • Patent number: 9468666
    Abstract: Endoglin has now been shown to be an important target of therapy to reduce disease symptoms associated with heart failure, particularly cardiac fibrosis. Soluble Endoglin is identified as an anatogonist to TGF?1 activity, while membrane-bound Endoglin is identified as a necessary component to promote TGF?1 activity in heart failure. The present invention therefore features methods and kits for treatment of subject having heart failure or a related disorder by administering a composition that decreases TGF?1 signaling through either direct inhibition of membrane-bound Endoglin or promoting expression of soluble Endoglin.
    Type: Grant
    Filed: July 31, 2012
    Date of Patent: October 18, 2016
    Assignee: Tufts Medical Center, Inc.
    Inventors: Navin K. Kapur, Richard H. Karas
  • Patent number: 9468667
    Abstract: Embodiments of the present invention provide Dermal Micro-organs (DMOs), methods and apparatuses for producing the same. Some embodiments of the invention provide a DMO including a plurality of dermal components, which substantially retain the micro-architecture and three dimensional structure of the dermal tissue from which they are derived, having dimensions selected so as to allow passive diffusion of adequate nutrients and gases to cells of the DMO and diffusion of cellular waste out of the cells. Some embodiments of the invention provide methods and apparatuses for harvesting the DMO. An apparatus for harvesting the DMO may include, according to some exemplary embodiments, a support configuration to support a skin-related tissue structure from which the DMO is to be harvested, and a cutting tool able to separate the DMO from the skin-related tissue structure.
    Type: Grant
    Filed: June 30, 2013
    Date of Patent: October 18, 2016
    Assignee: Medgenics Medical Israel Ltd.
    Inventors: Stephen F. Bellomo, Itzhak Lippin, Guillermo Alberto Piva, Lior Rosenberg, Mordechay Bukhman, Baruch S. Stern, David Shalhevet, Menachem D. Shavitt, Andrew L. Pearlman, Noam Shani, Einat Almon
  • Patent number: 9468668
    Abstract: Flavored chewable wafers containing nutritional supplement formulations suitable for enhancement of cell and mitochondrial function as well as providing antioxidants and aiding in weight loss and other desirable nutritional benefits comprises enriched formulations of phospholipids, specifically identified concentrations of phosphatidylglycerol, phosphatidic acid, phosphatidylethanolamine, phosphatidylcholine, glycolipids and phosphatidylserine along with inulin and other desirable active ingredients. These edible wafer lipid combinations can be used to treat mitochondrial disorders and other nutritional deficiencies associated with medical pathologies, chronic illnesses and syndromes, or to maintain lipid balance for normal mitochondrial function, and can be administered in pleasant tasting chewable wafers.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: October 18, 2016
    Assignee: ALLERGY RESEARCH GROUP, LLC
    Inventor: Robert Settineri
  • Patent number: 9468669
    Abstract: The invention provides methods and compositions for treating dysregulated blood glucose disorders.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: October 18, 2016
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventor: Amber Dianne Lockridge
  • Patent number: 9468670
    Abstract: Methods and composition for a melatonin signaling modulator-based diagnosis and therapy are described. For example, in certain aspects methods for administering an anti-tumor therapy using a melatonin signaling modulator are described. Furthermore, the invention provides compositions and methods for detecting biliary tract disease such as cholangiocarcinoma.
    Type: Grant
    Filed: April 2, 2012
    Date of Patent: October 18, 2016
    Assignees: Texas A&M University System, The United States of America as Represented by the Department of Veterans Affairs, Scott & White Healthcare
    Inventors: Gianfranco Alpini, Sharon DeMorrow, Shannon Glaser
  • Patent number: 9468671
    Abstract: Neural outgrowth in the central nervous system is achieved by administering chondroitinase AC and/or chondroitinase B to degrade chondroitin sulfate proteoglycans that inhibit or contribute to the inhibition of nervous tissue regeneration.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: October 18, 2016
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Elliott A. Gruskin, Jennifer F. Iaci, Andrea M. Vecchione, Sarah J. Kasperbauer, Gargi Roy
  • Patent number: 9468672
    Abstract: The present disclosure provides (a) isolated immunogenic PAA polypeptides; (b) isolated nucleic acid molecules encoding immunogenic PAA polypeptides; (c) vaccine compositions comprising an immunogenic PAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic PAA polypeptide; (d) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions; and (e) vaccine-based immunotherapy regimens which involve co-administration of a vaccine in combination with an immune-suppressive-cell inhibitor and an immune-effector-cell enhancer.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: October 18, 2016
    Assignee: Pfizer Inc.
    Inventors: Joseph John Binder, Helen Kim Cho, Michael Robert Dermyer, Karin Ute Jooss, Brian Gregory Pierce, Joyce Tsi Tan, Van To Tsai
  • Patent number: 9468673
    Abstract: fHBP is a protein in Neisseria meningitidis. Three families of fHBP are known. To increase the ability of a fHBP protein to elicit antibodies that are cross-reactive between the families, fHBP is selected or engineered to have a sequence which can elicit broad-spectrum bactericidal anti-meningococcal antibodies after administration to a host animal.
    Type: Grant
    Filed: January 8, 2013
    Date of Patent: October 18, 2016
    Assignee: GlaxoSmithKline Biologicals SA
    Inventors: Mariagrazia Pizza, Maria Scarselli, Marzia Monica Giuliani, Maria Arico, Rino Rappuoli
  • Patent number: 9468674
    Abstract: Described herein are methods of preventing and/or treating inflammation in a barrier surface structure in an individual in need thereof by orally administering to the individual an anti-inflammatory amount of secretory IgA.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: October 18, 2016
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Mark E. Cook, Jordan Marshall Sand, Lisa Ann Krugner-Higby, James Mukasa Ntambi
  • Patent number: 9468675
    Abstract: The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content.
    Type: Grant
    Filed: June 4, 2014
    Date of Patent: October 18, 2016
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Wolfgang Teschner, Hans-Peter Schwarz, Ruth Madlener, Sonja Svatos, Azra Pljevljakovic, Alfred Weber
  • Patent number: 9468676
    Abstract: The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis or hypercoagulation in patients having, or at risk of developing, diseases associated with abnormal blood coagulation or fibrinolysis and/or patients which are at increased risk or are being treated by a regimen that renders the patient at increased susceptibility to hypercoagulation or thrombosis such as patients who have previously had a stroke or heart attack or persons on a treatment regimen with a drug or chemotherapy and/or radiation that is associated with increased risk of thrombosis or hypercoagulation. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other coagulation cascade related proteins and optionally will further exhibit elevated C reactive protein prior to treatment.
    Type: Grant
    Filed: November 24, 2010
    Date of Patent: October 18, 2016
    Assignee: ALDERBIO HOLDINGS LLC
    Inventor: Jeffrey T. L. Smith
  • Patent number: 9468677
    Abstract: Compositions comprising TL1A-Ig fusion proteins and methods of their use, e.g., for the treatment of diseases and disorders associated with antigen-specific immune responses, are described. Also described are combination therapies that include the administration of a TNFRSF25 agonist and an interleukin (e.g., IL-2) and/or an mTOR inhibitor (e.g., rapamycin).
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: October 18, 2016
    Assignee: University of Miami
    Inventors: Eckhard R. Podack, Taylor H. Schreiber, Samia Q. Khan
  • Patent number: 9468678
    Abstract: The present disclosure provides isolated binding molecules that bind to human 4-1BB, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.
    Type: Grant
    Filed: May 13, 2014
    Date of Patent: October 18, 2016
    Assignee: Pfizer Inc.
    Inventors: Bianca Ahrens, Sangita M. Baxi, Timothy Scott Fisher, Richard Michael Jerome, Kathrin Ladetzki-Baehs, Theodore Oliphant, Leslie Lynne Sharp, Michael Tesar, Libbey Anne Yates, Moritz Zulley
  • Patent number: 9468679
    Abstract: Methods for preparing solid formulations of immunoglobulin single variable domains are provided. The methods are based on contacting solid carrier(s) with a liquid comprising the immunoglobulin single variable domains, e.g. by spraying the liquid onto the solid carrier(s), to cause granulation or coating of the carrier(s). During contacting the carrier is agitated, e.g. in a fluid bed, and the mixture of carrier and liquid is exposed to heat, e.g. a heated air stream, to evaporate the liquid.
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: October 18, 2016
    Assignee: Ablynx N.V.
    Inventors: Ann Debunne, Veronique De Brabandere
  • Patent number: 9468680
    Abstract: Drugs are screened for affects on inhibiting efflux pumps and blocking gap junction communication in tumors by culturing cells to thereby form self-assembled spheroids and incubating the spheroids. Uptake of a substrate of the efflux pump and distribution of a substrate for the efflux pump within the spheroids is imaged to thereby select drugs that inhibit the efflux pump or do not block gap junction communication. Selected drugs can then be employed to treat a tumor.
    Type: Grant
    Filed: September 20, 2012
    Date of Patent: October 18, 2016
    Assignee: Brown University
    Inventors: Jeffrey R. Morgan, Toni-Marie Achilli, Anubhav Tripathi, Stephanie McCalla
  • Patent number: 9468681
    Abstract: Described herein are carrier nanoparticles comprising a polymer containing a polyol coupled to a polymer containing a boronic acid, configured to present the polymer containing a boronic acid to an environment external to the nanoparticle. Targeted versions of the described nanoparticles are also described, as are related compositions, methods and systems.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: October 18, 2016
    Assignee: California Institute of Technology
    Inventors: Mark E. Davis, Han Han
  • Patent number: 9468682
    Abstract: According to this invention, compositions and methods for increasing the extent of penetration of a biologically active substance into the tissues and organs are proposed, the methods comprising administration of the biologically active substance in combination with one or more chaotropic agents, e.g., ammonium sulfate.
    Type: Grant
    Filed: April 5, 2013
    Date of Patent: October 18, 2016
    Assignee: Joint-stock company “High Tech”
    Inventor: Olga Klimova
  • Patent number: 9468683
    Abstract: The present invention relates to compositions and pharmaceutical compositions having a hyaluronic acid; a chitosan; and at least one ionic compound in hydrogel form, their use in medical applications and methods of making same as well as medical devices comprising same.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: October 18, 2016
    Assignee: UNIVERSITY OF GENEVA
    Inventors: Olivier Jordan, Sema Gwendolyn Kaderli, Robert Gurny
  • Patent number: 9468684
    Abstract: The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: October 18, 2016
    Assignee: Covidien LP
    Inventors: Steven Bennett, Nathaniel Mast, Kevin Lavigne, Walter Skalla
  • Patent number: 9468685
    Abstract: Provided are pharmaceutical liquid formulations of G-CSF, which are stable over a long time period and substantially free of excipients, as well as ready-to-use syringes containing such formulations and corresponding kits.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: October 18, 2016
    Assignee: RATIOPHARM GMBH
    Inventors: Walter Hinderer, Heinz Lubenau
  • Patent number: 9468686
    Abstract: A solution in water comprising the following components at the following concentrations: (a) N×(70 to 130) g/L polyethylene glycol (PEG) having an average molecular weight of 2500 to 4500; (b) N×(1.6 to 4.0) g/L sodium chloride; (c) N×(0.2 to 0.6) g/L potassium chloride; (d) N×(0.6 to 2.2) g/L sodium bicarbonate; (e) N×an amount of preservative; (f) optionally N x an amount of flavouring; and (g) optionally N×an amount of sweetener, where N is in the range of 2 to 8. The solution is a concentrate for dilution. In use it is diluted N-fold with water to provide a solution for administration to a subject for the treatment of constipation or faecal impaction. Also provided are solutions, kits, unit doses and methods that comprise or use the solutions.
    Type: Grant
    Filed: January 28, 2014
    Date of Patent: October 18, 2016
    Assignee: NORGINE BV
    Inventors: Chris Seldon, Dawn Padfield, Frances Morrissey
  • Patent number: 9468687
    Abstract: Pharmaceutical compositions comprising a nucleic acid, a gene delivery polymer, and at least one adjunctive chemotherapeutic drug for the treatment of mammalian cancer or hyperproliferative disorders and methods of using thereof for the treatment of mammalian cancer or hyperproliferative disorders by intratumoral, intraperitoneal or systemic injection.
    Type: Grant
    Filed: January 6, 2014
    Date of Patent: October 18, 2016
    Assignee: CLSN LABORATORIES, INC.
    Inventors: Jason G. Fewell, Majed Matar, Jennifer Rice, Danny H. Lewis, Khursheed Anwer
  • Patent number: 9468688
    Abstract: The present invention provides a novel boron carrier compound that can be used for boron neutron capture therapy for cancer, and that can realize improvement in the efficiency of a Drug Delivery System (DDS) and an increase in the boron concentration in a tumor. The present invention provides a boron cluster-modified PEG lipid derivative represented by Formula (I): wherein, m and n are each independently an integer of 1-4, q is an integer of 1-280, and R1 and R2 are each independently a hydrocarbon group with a carbon number of 8-22, and a molecular assembly containing the same.
    Type: Grant
    Filed: August 22, 2013
    Date of Patent: October 18, 2016
    Assignee: UNIVERSITY OF TSUKUBA
    Inventors: Akira Matsumura, Kei Nakai, Makoto Shirakawa
  • Patent number: 9468689
    Abstract: Disclosed are methods, compositions and uses of high concentration antibody or immunoglobulin formulations for subcutaneous, intramuscular, transdermal or other local (regional) administration, in a volume of than 3, less than 2 or less than 1 ml. Preferably, the formulation contains a high concentration formulation (HCF) buffer comprising phosphate, citrate, polysorbate 80 and mannitol at a pH of about 5.2. The formulation more preferably comprises at least 100, 150, 200, 250 mg/ml or 300 mg/ml of antibody. The methods for preparing the high concentration formulation include ultrafiltration and diafiltration to concentrate the antibody and exchange the medium for HCF buffer. Other embodiments concern use of non-G1m1 (nG1m1) allotype antibodies, such as G1m3 and/or a nG1m1,2 antibodies. The nG1m1 antibodies show decreased immunogenicity compared to G1m1 antibodies.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: October 18, 2016
    Assignee: Immunomedics, Inc.
    Inventors: Li Zeng, Rohini Mitra, Edmund A. Rossi, Hans J. Hansen, David M. Goldenberg
  • Patent number: 9468690
    Abstract: A novel gene delivery system and recombinant adenovirus includes a decorin-encoding sequence to enhance transduction efficiency of transgenes. A pharmaceutical anti-tumor composition includes the recombinant adenovirus, as well as a pharmaceutical composition having improved tissue penetration potency and a pharmaceutical composition for treating a disease or disorder associated with accumulation of excess extracellular matrix.
    Type: Grant
    Filed: February 24, 2006
    Date of Patent: October 18, 2016
    Assignee: GENEMEDICINE CO., LTD.
    Inventors: Chae-Ok Yun, Joo-Hang Kim
  • Patent number: 9468691
    Abstract: The present invention discloses biocompatible, stable curcumin or its derivatives coated ultra-small super paramagnetic iron oxide nanoparticles (USPION) for biomedical applications. Disclosed herein is also a simple one-pot process for the synthesis of biocompatible, stable curcumin or its derivatives coated ultra-small superparamagnetic iron oxide nanoparticles in absence of a linker or binder. The curcumin or its derivatives coated ultra-small super paramagnetic iron oxide nanoparticles of the present invention retains the medicinal, radical scavenging and fluorescence properties of curcumin.
    Type: Grant
    Filed: January 17, 2013
    Date of Patent: October 18, 2016
    Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
    Inventors: Alias Joy Pattayil, Kunnoth Naduvilidam Jayaprabha
  • Patent number: 9468692
    Abstract: Imaging agents are described that comprise labeled substrates capable of being introduced into cells via the cystine/glutamate antiporter. The substrates may be used for imaging or detecting oxidative stress in cells by introducing the labeled agents into cells via the cystine/glutamate antiporter and subsequent detection.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: October 18, 2016
    Assignee: General Electric Company
    Inventors: Bruce Allan Hay, Jack Mathew Webster
  • Patent number: 9468693
    Abstract: Imaging agents are described that comprise labeled substrates capable of being introduced into cells via the cystine/glutamate antiporter. The substrates may be used for imaging or detecting oxidative stress in cells by introducing the labeled agents into cells via the cystine/glutamate antiporter and subsequent detection.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: October 18, 2016
    Assignee: General Electric Company
    Inventors: Bruce Allan Hay, Jack Mathew Webster
  • Patent number: 9468694
    Abstract: The invention relates to a process for preparation of a compound of formula (I): R1 is selected from C1-6alkyl, C2-6alkenyl, and C2-6alkynyl; which comprises: (i) reaction with fluoride, suitably [18F]fluoride, of a corresponding compound of formula (II): wherein R2 is selected from hydrogen, C1-10alkyl, C1-10haloalkyl, C6-14aryl, C6-14arylalkyl, —(CH2CH2O)q—CH3 wherein q is an integer of from 1 to 10; R1 is as defined for the compound of formula (I); and R3 is a leaving group. Certain novel precursors of formula (II) and radiopharmaceutical kits containing such precursors are also claimed.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: October 18, 2016
    Assignee: GE Healthcare Limited
    Inventors: Anthony Eamon Storey, Clare Louise Jones, Denis Raymond Christophe Bouvet, Nicolas Lasbistes, Steven Michael Fairway, Lorenzo Williams, Alexander Mark Gibson, Robert James Nairne, Farhad Karimi, Bengt Langstrom
  • Patent number: 9468695
    Abstract: A UV device includes a housing having a portion configured to be removably attached to a smart device, a UV light source disposed within the housing, wherein the UV light source is configured to provide output of UV light in response to an operating powered, a communication mechanism disposed within the housing, wherein the communication mechanism is configured to receive instructions from the smart device, a control mechanism disposed within the housing, wherein the control mechanism is coupled to the UV light source, and to the communication mechanism, wherein the control mechanism is configured to provide the operating power to the UV light source, in response to the instructions received from the smart device.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: October 18, 2016
    Assignee: RAYVIO CORPORATION
    Inventors: Yitao Liao, Robert C. Walker
  • Patent number: 9468696
    Abstract: A sink insert for cleaning medical or surgical devices having lumens includes a basin and at least two pumps. The basin is shaped to be inserted into a sink and to hold cleaning liquid, and includes an additive reservoir integrally formed in its floor, having additive fill lines defining a plurality of pre-calibrated volume measurement areas for measurement of additives. Basin fill lines positioned on one or more side walls of the basin define a plurality of pre-calibrated volume measurement areas for measurement of a liquid filled into the basin to form the cleaning liquid. At least one of the two pumps has an inlet tube for drawing the cleaning liquid from the basin into the pump, and an outlet tube for pressurized output of the cleaning liquid directed to the medical or surgical device. One or more of the pumps is removable from the sink insert.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: October 18, 2016
    Assignee: PURE PROCESSING LLC
    Inventor: Daniel Leonard Gusanders
  • Patent number: 9468697
    Abstract: A method of delivering a volatile material to the atmosphere in a continuous manner is disclosed. The method includes providing a delivery engine having a reservoir that includes a volatile material mixture. The volatile material mixture includes about 40% to about 100%, by total weight, of the volatile materials each having a vapor pressure at 25° C. of less than about 0.1 torr. The delivery system also includes a microporous membrane enclosing the reservoir, wherein the microporous membrane comprises an average pore size of about 0.01 to about 0.03 microns.
    Type: Grant
    Filed: January 25, 2016
    Date of Patent: October 18, 2016
    Assignee: The Procter & Gamble Company
    Inventors: Dana Paul Gruenbacher, Jason John Olchovy, Scott Kendyl Stanley, James Douglas Still, Rhonda Jean Jackson, Zaiyou Liu, Walter Sordo, Stefano Deflorian, Cedric Morhain